RJ Tesi, M.D., is the co-founder and CEO of INmune Bio (NASDAQ: INMB), a publicly-traded, clinical-stage biotechnology company developing therapies that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials, the DN-TNF product platform, call XPro™ and the Natural Killer Cell Priming Platform which includes INKmune™.
We now know how important white matter is to our overall brain health and cognitive ability, as well as how declines in white matter structure are correlated with impairments in brain function.